Clinical Trial Update: Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase II trial of Velcade (bortezomib) for relapsed or refractory T-cell prolymphocytic leukemia has been withdrawn (sponsor: Stanford University).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Stanford University | Conditions: Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN